$TAK insider trading
Over the last 12 months, Takeda Pharmaceutical insiders reported no purchases and 17 sales totaling $10.3M across SEC Form 4 filings. 6% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $10.3M 17 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 13 distinct reporters
- 10b5-1 share
- 6% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Plump Andrew StewartPresident, R&D · O·D | ▼ Sale | 19,651 | $18.49 | $363K | -7% | plan · indirect |
| Aug 18, 2026 | Greenway Nicola Deidre PetalChief Human Resources Officer · O | ▼ Sale | 12,980 | $18.11 | $235K | -24.5% | — |
| Aug 11, 2026 | Shannon Elaine MaryPres., Global Supply & Quality · O | ▼ Sale | 20,363 | $17.55 | $357K | -23.2% | — |
| Aug 10, 2026 | Farajallah Awny Samaan BotrosChief Medical Officer · O | ▼ Sale | 14,006 | $17.1 | $240K | -10.8% | — |
| Aug 10, 2026 | Ibrahim Ramy Riad AhmedPresident, PDT BU · O | ▼ Sale | 7,277 | $17.1 | $124K | -6.6% | — |
| Aug 10, 2026 | Pacheco Rhonda JanicePresident, U.S. Business Unit · O | ▼ Sale | 16,901 | $17.1 | $289K | -8.5% | — |
| Aug 10, 2026 | Duprey Lauren RusckowskiChief Transformation Officer · O | ▼ Sale | 47,586 | $17.1 | $814K | -17.4% | — |
| Aug 10, 2026 | Plump Andrew StewartPresident, R&D · O·D | ▼ Sale | 165,393 | $17.1 | $2.8M | -17.7% | — |
| Aug 10, 2026 | Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev · O | ▼ Sale | 22,957 | $17.1 | $393K | -11.5% | — |
| Aug 10, 2026 | Bitetti Teresa MariePresident, OBU · O | ▼ Sale | 50,012 | $17.1 | $855K | -16.6% | — |
| Aug 10, 2026 | Shannon Elaine MaryPres., Global Supply & Quality · O | ▼ Sale | 3,978 | $17.1 | $68K | -5.9% | — |
| Aug 10, 2026 | Ricci GabrieleChief Data & Tech. Officer · O | ▼ Sale | 25,088 | $17.1 | $429K | -12.8% | — |
| Aug 10, 2026 | Greenway Nicola Deidre PetalChief Human Resources Officer · O | ▼ Sale | 6,774 | $17.1 | $116K | -11.3% | — |
| Aug 10, 2026 | Kim Julie So-YoungPresident and CEO · O·D | ▼ Sale | 89,090 | $17.1 | $1.5M | -18.5% | — |
| Aug 10, 2026 | Platford Giles RichardPresident, IBU · O | ▼ Sale | 31,083 | $17.1 | $532K | -9% | — |
| Aug 10, 2026 | Furney Natalie Anne MarieGlobal General Counsel · O | ▼ Sale | 30,868 | $17.1 | $528K | -13.1% | — |
| Aug 10, 2026 | Greenway Nicola Deidre PetalChief Human Resources Officer · O | ▼ Sale | 34,603 | $17.51 | $606K | -36.7% | 2 tranches |
Every $TAK filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Takeda Pharmaceutical filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TAK feed.